|
1) Blondel-Hill E, Henry DA, Speert DP. Pseudomonas. In: Murray PR, Baron EJ, James HJ, et al, editors. Manual of Clinical Microbiology. 9th ed: American Society for Microbiology; 2007. p.734-48
|
|
|
|
|
2) Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002; 162: 1849-58
|
|
|
|
|
3) Garau J, Gomez L. Pseudomonas aeruginosa pneumonia. Curr Opin Infect Dis. 2003; 16: 135-43
|
|
|
|
|
|
4) Geckler RW, Gremillion DH, McAllister CK, et al. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J Clin Microbiol. 1977; 6: 396-9
|
|
|
|
|
|
5) Kopelman TR. Can empiric broad-spectrum antibiotics for ventilator-associated pneumonia be narrowed based on Gramʼs stain results of bronchoalveolar lavage fluid. Am J Surg. 2006; 192: 812-6
|
|
|
|
|
|
6) Schentag JJ, Vari AJ, Winslade NE, et al. Treatment with aztreonam or tobramycin in critical care patients with nosocomial Gram-negative pneumonia. Am J Med. 1985; 78(2A): 34-41
|
|
|
|
|
|
7) Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med. 1996; 156(18): 2121-6
|
|
|
|
|
|
8) Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis. 1998; 17: 701-8
|
|
|
|
|
|
9) Siegman-Igra Y, Ravona R, Primerman H, et al. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis. 1998; 2: 211-5
|
|
|
|
|
|
10) Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730-51
|
|
|
|
|
|
11) Livermore DM. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995; 8: 557-84
|
|
|
|
|
|
12) Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare？ Clin Infect Dis. 2002; 34: 634-40
|
|
|
|
|
|
13) Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother. 2001; 47: 247-50
|
|
|
|
|
|
14) Langaee TY, Gagnon L, Huletsky A. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC beta-lactamase expression. Antimicrob Agents Chemother. 2000; 44: 583-9
|
|
|
|
|
|
15) Livermore DM. Clinical significance of beta-lactamase induction and stable derepression in Gram-negative rods. Eur J Clin Microbiol. 1987; 6: 439-45
|
|
|
|
|
|
16) Poole K, Tetro K, Zhao Q, et al. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob Agents Chemother. 1996; 40: 2021-8
|
|
|
|
|
|
17) Sobel ML, Hocquet D, Cao L, et al. Mutations in PA3574 (nalD) lead to increased MexAB-OprM expression and multidrug resistance in laboratory and clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005; 49: 1782-6
|
|
|
|
|
|
18) Li J, Turnidge J, Milne R, et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001; 45: 781-5
|
|
|
|
|
|
19) Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006; 6: 589-601
|
|
|
|
|
|
20) Empel J, Filczak K, Mrowka A, et al. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J Clin Microbiol. 2007; 45: 2829-34
|
|
|
|
|
|
21) Pai H, Kim J, Lee JH, et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2001; 45: 480-4
|
|
|
|
|
|
22) Quale J, Bratu S, Gupta J, et al. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2006; 50: 1633-41
|
|
|
|
|
|
23) Gilbert DN, Kohlhepp SJ, Slama KA, et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob Agents Chemother. 2001; 45: 883-92
|
|
|
|
|
|
24) Kumazawa J, Yagisawa M. The history of antibiotics: the Japanese story. J Infect Chemother. 2002; 8: 125-33
|
|
|
|
|
25) Schulin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother. 2002; 49: 403-6
|
|
|
|
|
|
26) Tomas M, Doumith M, Warner M, et al. Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2010; 54: 2219-24
|
|
|
|
|
|
27) Falagas ME, Sideri G, Vouloumanou EK, et al. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J. 2009; 28: 123-7
|
|
|
|
|
|
28) Korvick JA, Peacock JE Jr, Muder RR, et al. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol. Antimicrob Agents Chemother. 1992; 36: 620-5
|
|
|
|
|
|
29) Lepper PM, Grusa E, Reichl H, et al. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002; 46: 2920-5
|
|
|
|
|
|
30) Matthaiou DK, Michalopoulos A, Rafailidis PI, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med. 2008; 36: 807-11
|
|
|
|
|